Oncology & Cancer

Ibrutinib continues strong showing against mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle ...

Oncology & Cancer

Dose analysis predicts non-Hodgkin lymphoma survival

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art ...

Oncology & Cancer

TCE exposure linked to increased risk of some cancers

Trichloroethylene (TCE) exposure has possible links to increased liver cancer risk, and the relationship between TCE exposure and risks of cancers of low incidence and those with confounding by lifestyle and other factors ...

Oncology & Cancer

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

Immunology

Study finds how to shutdown cancer's powerful master protein

The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...

page 2 from 5